Study Examines GLP-1 Receptor Agonists and Insulin Discontinuation in Diabetes Patients
A new study led by Dr. Kasia Lipska, an associate professor of medicine specializing in endocrinology and metabolism at Yale School of Medicine, investigated the role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in helping patients with type 2 diabetes discontinue insulin therapy. Published in the Annals of Internal Medicine, the research utilized electronic health records from the U.S. Department of Veterans Affairs to analyze the outcomes of approximately 9,000 patients who began treatment with GLP-1RAs, sodium–glucose cotransporter-2 inhibitors (SGLT-2is), or dipeptidyl peptidase-4 inhibitors (DPP-4is). The study aimed to determine whether GLP-1RAs could facilitate the safe discontinuation of insulin, a treatment that, while effective, can be burdensome due to the need for daily injections and monitoring, as well as the risk of low blood sugar episodes.
Despite the expectation that GLP-1RAs would significantly aid in insulin discontinuation, the results revealed that all groups, including those on GLP-1RAs, discontinued insulin at comparable rates. Dr. Lipska expressed surprise at the findings, noting that she anticipated a more pronounced effect from GLP-1RAs. She suggested that the lack of increased discontinuation rates might be attributed to the study's non-randomized design, which relied on routine clinical data rather than controlled trial conditions.
The study also highlighted that many patients did not reach full dosing levels of GLP-1RAs, instead using lower doses that may not have been as effective as those available on the market. This raises concerns about the broader issue of diabetes management, particularly the absence of standardized guidelines for safely discontinuing insulin therapy. Dr. Lipska pointed out that most diabetes training focuses on initiating and adjusting insulin doses rather than the withdrawal process.
She emphasized that achieving target blood sugar levels should signal a potential reduction in insulin dosage, yet many patients remain on insulin due to clinician uncertainty about the withdrawal process. Dr. Lipska concluded that prescribing GLP-1RAs is merely the first step; to assist patients in safely discontinuing insulin, healthcare providers require better guidance on when and how to do so. The study was conducted with the support of the U.S. Department of Veterans Affairs and included contributions from other Yale researchers, including Dr. Pradeep Mutalik, Dr. Barbara Gulanski, Dr. Mihaela Aslan, and Dr. Lei Yan.




